Clinical course of hypertrophic cardiomyopathy patients implanted with a transvenous or subcutaneous defibrillator.
Pietro FranciaMatteo ZiacchiCarmen AdduciErnesto AmmendolaPaolo PieragnoliPaolo De FilippoAntonio RapacciuoloValeria RellaFederico MiglioreStefano VianiMaria Beatrice MusumeciElena BiaginiMariolina LovecchioRossella BaldiniGiulio FalasconiCamillo AutoreMauro BiffiFranco CecchiPublished in: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2023)
Hypertrophic cardiomyopathy patients implanted with a S-ICD had lower 5-year risk of appropriate and inappropriate ICD therapies as well as of major lead-related complications as compared to those implanted with a TV-ICD. Long-term comparative follow-up studies will clarify whether the lower incidence of major lead-related complications will translate into a morbidity or survival benefit.